文章预览
SCI 9 December 2025 A Prospective Phase II Trial of First-line Osimertinib for Patients with EGFR Mutation-positive Non-small Cell Lung Cancer and Poor Performance Status (OPEN/TORG2040) (Journal of Thoracic Oncology, IF: 21.1) Tomoya Fukui, MD, PhD, Nobuaki Mamesaya, MD, PhD, Toshiaki Takahashi, MD,PhD, Kazuma Kishi, MD, Takahiro Yoshizawa, MD, Takaaki Tokito, MD, PhD, KoichiAzuma, MD, Kei Morikawa, MD, Satoshi Igawa, MD, PhD, Yusuke Okuma, MD, YutaYamanaka, MD, Shinobu Hosokawa, MD, PhD, Takashi Kasai, MD, Ken Masubuchi,MD, Shinji Nakamichi, MD, PhD, Masaharu Aga, MD, Jiichiro Sasaki, MD, PhD, AkikoKada, MPH, Akiko M. Saito, MD, PhD, Katsuhiko Naoki, MD, PhD, Hiroaki Okamoto,MD, PhD, the Thoracic Oncology Research Group (TORG) CORRESPONDENCE TO: tofukui@med.kitasato-u.ac.jp Introduction 简介 Osimertinib is the first-line treatment for patients with non-small cell lung cancer (NSCLC) who have EGFR mutations and favorable performance status (PS). Despite increasing clinical data on
………………………………
